Showing 2941-2950 of 5621 results for "".
- Eversight Partners with LighTopTech to Improve Imaging Modalities for Eye Tissueshttps://modernod.com/news/eversight-partners-with-lightoptech-to-improve-imaging-modalities-for-eye-tissues/2482310/Eversight announced a 4-year partnership with LighTopTech that aims to improve imaging modalities for eye tissues in both clinical and research settings. Financial terms of the deal were not disclosed. As part of th
- Clearside Biomedical Publishes Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS) Injectionhttps://modernod.com/news/clearside-biomedical-publishes-consensus-guidelines-for-drug-delivery-via-suprachoroidal-space-scs-injection/2482288/Clearside Biomedical announced that new guidelines that represent best practices for injection into the suprachoroidal space have been published in "RETINA, The Journal of Retinal and Vitreous Diseases." The publication, entitled, “Suprachoroidal Space Injection Techniqu
- FDA Approves First Interchangeable Biosimilars to Eyleahttps://modernod.com/news/fda-approves-first-interchangeable-biosimilars-to-eylea/2482286/The FDA has approved Biocon’s Yesafili (aflibercept-jbvf) and Samsung Bioepis and Biogen’s Opuviz (aflibercept-yszy) as the first interchangeable biosimilars to Eylea (aflibercept). Yesafili and Opuviz are used to treat wet age-related macular degeneratio
- Johnson & Johnson to Debut EYE-RD Global Registry at ARVOhttps://modernod.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/Johnson & Johnson announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The company's two oral presentations wil
- Aldeyra Therapeutics Announces Planned Pivotal Clinical Trial for RP Drug Candidatehttps://modernod.com/news/aldeyra-therapeutics-announces-planned-pivotal-clinical-trial-for-retinitis-pigmentosa-drug-candidate/2482247/Aldeyra Therapeutics hosted the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City on April 25 where it presented recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the treatment of retinitis pigmentosa.
- False Claims Act Complaint Filed Against Regeneron for Fraudulent Drug Pricing Reportinghttps://modernod.com/news/false-claims-act-complaint-filed-against-regeneron-for-fraudulent-drug-pricing-reporting/2482228/The US Department of Justice (DOJ) has filed a complaint under the False Claims Act (FCA) against Regeneron alleging that the company fraudulently inflated Medicare reimbursement rates for Eylea (aflibercept) by knowingly submitting false average sales price reports to CMS that excluded
- Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNIhttps://modernod.com/news/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-aqueous-outflow-restorative-procedure-with-omni/2482226/Sight Sciences announced the results as published in the American Journal of Ophthalmology (AJO) International of a large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery (MIGS) technologies.
- Pantheon Vision Secures a Second Tranche of Funding to Advance Bioengineered Corneal Implantshttps://modernod.com/news/pantheon-vision-secures-a-second-tranche-of-funding-to-advance-bioengineered-corneal-implants/2482197/Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants, announced the closing of $1.8 million in a second tranche from KeraLink International (KLI). This comes following a previous $2.5 million investment from KLI last year, bringing the total
- Regenxbio Announces Lancet Publication of Phase 1/2a Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-announces-lancet-publication-of-phase-12a-study-evaluating-abbv-rgx-314-as-a-one-time-gene-therapy-for-wet-amd/2482186/Regenxbio announced the publication of results from the phase 1/2a trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD). Two-year data were
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo